Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 405.73Cr 351.61Cr 332.33Cr 301.7Cr 565.46Cr 39TCr 568.83Cr 3.97TCr 1.53TCr 20TCr 1.52TCr 1.49TCr 63TCr P/E 2026 *
9.24x
P/E 2027 * 8.38x
Enterprise Value 404.48Cr 350.52Cr 331.3Cr 300.77Cr 563.71Cr 39TCr 567.08Cr 3.96TCr 1.53TCr 20TCr 1.52TCr 1.49TCr 63TCr EV / Sales 2026 *
3.04x
EV / Sales 2027 * 2.49x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 week+5.27%
1 month+20.78%
3 months+60.36%
6 months+29.91%
Current year+20.90%
1 week 1,160
Extreme 1160
1,264
1 month 975.5
Extreme 975.5
1,264
3 years 554.83
Extreme 554.83
2,020
5 years 335
Extreme 335
2,020
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%+5.27%+49.52%-20.18% 403.84Cr
+0.15%+1.21%+48.79%+97.65% 1,01300Cr
+0.03%+0.07%+51.47%+65.55% 64TCr
-0.20%+4.62%+21.39%+72.57% 46TCr
+0.53%+4.26%+40.29%+38.70% 35TCr
+0.39%+2.35%+17.96%+23.87% 26TCr
+0.17%+4.17%+6.96%+10.93% 25TCr
+0.19%-3.81%+37.81%+44.35% 20TCr
-1.20%-5.64%-24.09%-59.10% 19TCr
+0.94%+1.39%+33.21%+95.16% 18TCr
Average +0.11%-0.62%+28.33%+36.95% 39.6TCr
Weighted average by Cap. +0.11%+0.32%+34.35%+59.58%

Financials

2026 *2027 *
Net sales 133.2Cr 115.43Cr 109.1Cr 99Cr 185.63Cr 13TCr 186.74Cr 1.3TCr 503.27Cr 6.48TCr 500.35Cr 489.24Cr 21TCr 139.95Cr 121.28Cr 114.63Cr 104.07Cr 195.05Cr 13TCr 196.21Cr 1.37TCr 528.8Cr 6.81TCr 525.73Cr 514.06Cr 22TCr
Net income 47Cr 41Cr 39Cr 35Cr 66Cr 4.55TCr 66Cr 463.75Cr 179.2Cr 2.31TCr 178.16Cr 174.2Cr 7.36TCr 53Cr 46Cr 43Cr 39Cr 74Cr 5.08TCr 74Cr 518.21Cr 200.24Cr 2.58TCr 199.08Cr 194.66Cr 8.22TCr
Net Debt -1.25Cr -1.08Cr -1.02Cr -92.95L -1.74Cr -119.92Cr -1.75Cr -12Cr -4.72Cr -61Cr -4.7Cr -4.59Cr -193.87Cr -57Cr -49Cr -47Cr -42Cr -79Cr -5.47TCr -80Cr -557.36Cr -215.37Cr -2.77TCr -214.12Cr -209.37Cr -8.84TCr
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
34.38USD
Average target price
49.00USD
Spread / Average Target
+42.52%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!